CA2586073A1 - Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents - Google Patents

Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents Download PDF

Info

Publication number
CA2586073A1
CA2586073A1 CA002586073A CA2586073A CA2586073A1 CA 2586073 A1 CA2586073 A1 CA 2586073A1 CA 002586073 A CA002586073 A CA 002586073A CA 2586073 A CA2586073 A CA 2586073A CA 2586073 A1 CA2586073 A1 CA 2586073A1
Authority
CA
Canada
Prior art keywords
arom
group
cndot
alkyl
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002586073A
Other languages
English (en)
French (fr)
Inventor
Helene Munier-Lehmann
Dominique Douguet
Gilles Labesse
Sylvie Pochet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
Institut Pasteur
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2586073A1 publication Critical patent/CA2586073A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002586073A 2004-11-05 2005-11-04 Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents Abandoned CA2586073A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04292629A EP1655288A1 (en) 2004-11-05 2004-11-05 Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents
EP04292629.5 2004-11-05
PCT/EP2005/012346 WO2006048336A2 (en) 2004-11-05 2005-11-04 Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents

Publications (1)

Publication Number Publication Date
CA2586073A1 true CA2586073A1 (en) 2006-05-11

Family

ID=34931507

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002586073A Abandoned CA2586073A1 (en) 2004-11-05 2005-11-04 Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents

Country Status (7)

Country Link
US (1) US20080096907A1 (cg-RX-API-DMAC10.html)
EP (2) EP1655288A1 (cg-RX-API-DMAC10.html)
JP (1) JP2008519001A (cg-RX-API-DMAC10.html)
CN (1) CN101098860A (cg-RX-API-DMAC10.html)
BR (1) BRPI0517646A (cg-RX-API-DMAC10.html)
CA (1) CA2586073A1 (cg-RX-API-DMAC10.html)
WO (1) WO2006048336A2 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI445696B (zh) * 2010-11-29 2014-07-21 Univ Nat Yang Ming 標靶人類胸線核苷酸激酶誘導惡性腫瘤中的dna修復毒性
RU2475482C1 (ru) * 2012-01-13 2013-02-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный университет" Комплексное соединение 5-гидрокси-6-метилурацила с сукцинатом натрия и способ его получения
PL3432887T3 (pl) * 2016-03-22 2021-05-17 Glaxosmithkline Intellectual Property Development Limited Środek przeciwgruźliczy
US20220041627A1 (en) * 2018-12-04 2022-02-10 University Of Maryland, Baltimore Prodrugs of anti-cancer and anti-autoimmune diseases therapeutic agents, and methods of making and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1959705A1 (de) * 1969-11-28 1971-06-03 Bayer Ag Verfahren zur Herstellung von Uracilderivaten
JPH08325238A (ja) * 1995-05-30 1996-12-10 Asahi Glass Co Ltd 5−トリフルオロメチルウラシル誘導体およびその製造方法
ES2157366T3 (es) * 1995-06-09 2001-08-16 Hoffmann La Roche Derivados de pirimidindiona, pirimidintriona, triacindiona como antagonistas de receptores alfa-1-adrenergicos.
US6608197B2 (en) * 2000-01-25 2003-08-19 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
WO2002061110A2 (en) * 2001-01-29 2002-08-08 Bio-Rad Laboratories, Inc. Nucleic acid derivatives
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists

Also Published As

Publication number Publication date
BRPI0517646A (pt) 2008-10-14
WO2006048336A3 (en) 2006-10-12
JP2008519001A (ja) 2008-06-05
EP1814867A2 (en) 2007-08-08
EP1655288A1 (en) 2006-05-10
WO2006048336B1 (en) 2006-11-09
WO2006048336A2 (en) 2006-05-11
CN101098860A (zh) 2008-01-02
US20080096907A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
Dolle et al. A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors
Ashton et al. Synthesis and antiherpetic activity of (.+-.)-9-[[(Z)-2-(hydroxymethyl) cyclopropyl] methyl] guanine and related compounds
US5723609A (en) Bis (hydroxymethyl) cyclobutyl purines
JP5297414B2 (ja) キサンチンオキシダーゼ阻害剤
EP2909189B1 (en) Heteroaryl linked quinolinyl modulators of ror-gamma-t
PL143010B1 (en) Process for preparing novel derivatives of 1,2,3,5-tetrahydroimidazo/2,1-b/quinazoline
US4400387A (en) Indolizine derivatives and uses in therapeutics
US20060167253A1 (en) Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
Tian et al. Design, synthesis and biological evaluation of novel 6-substituted pyrrolo [3, 2-d] pyrimidine analogues as antifolate antitumor agents
US7098220B2 (en) Imidazopyridine derivatives, preparation method and pharmaceutical compositions containing same
CA2366624C (en) 2-hydroxy methylcyclopro pylidenemethyl purines and -pyrimidines as antiviral agents
Brown et al. Inhibitors of Bacillus subtilis DNA polymerase III. 6-(Arylalkylamino) uracils and 6-anilinouracils
CN109369623A (zh) 一种取代1,2,3三氮唑类二芳基嘧啶衍生物及其制备方法与应用
CN112771048B (zh) 流感病毒复制抑制剂及其中间体和用途
US20080096907A1 (en) Aryl, Pyrimidyl Compounds, Pharmaceutical Compositions Comprising them, Their Use as Antimicrobial Agents
CN110078735B (zh) 具有抗肿瘤活性的吡咯并嘧啶化合物及其用途
JPH04230669A (ja) 置換ピリミジン誘導体
JP2011111433A (ja) ウレイド構造を有するウラシル化合物又はその塩
Kaiser et al. A novel type of acyclic nucleoside phosphonates derived from 2-(phosphonomethoxy) propanoic acid
JPH05117273A (ja) 医薬化合物
JPH0643421B2 (ja) ピリミジン誘導体
HK1091820A (en) Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents
EP0303348B1 (en) 2-amino-5-hydroxy-4-pyrimidones
DE69427394T2 (de) Kondensierte heterocyclische glutaminsäurederivate als antiproliferative mittel
JPH11510797A (ja) 4−アリール−チオ−ピリジン−2(1h)−オン、それらを含有する医薬及びそのhivに関連する疾病の治療における使用

Legal Events

Date Code Title Description
FZDE Discontinued